Latest news:

BioStock article: New patent notice rounds off an eventful six months for Follicum

BioStock published an article on 25 June 2020 about Follicum, which can be read in full below. During the first half of 2020, Follicum has started, paused and resumed a phase II study with its primary candidate FOL-005. An international patent application has been filed regarding its newly developed topical formulation as a carrier of […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Follicum's presentation at LSX World Congress 2020

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




26 Oct 20

Follicum will attend the BIO-Europe conference in Munich, Germany, on 26-28 October 2020 The confere...